Arm 1 Crossover to Arm 2
PD
DISEASE PROGRESSION
Seventeen of 37 patients (45.9%) who experienced disease progression while taking alisertib crossed over to arm 2. This occurred mostly commonly after 2 (n = 5) or 6 cycles (n = 5) of alisertib; however, 4 patients initiated combination treatment after 17 to 26 cycles. All patients discontinued treatment due to PD after undergoing 1 to 14 cycles of combination therapy. One partial response was observed with combination treatment. The mPFS after crossover was 3.7 months.